X4 PHARMACEUTICALS, INC Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
X4 PHARMACEUTICALS, INC (XFOR) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 18.59 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-06
- X4 PHARMACEUTICALS, INC antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-06-30 was 18.59M shares, a 483.40% increase year-over-year.
- X4 PHARMACEUTICALS, INC antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 18.46M shares, a 491.54% increase year-over-year.
- X4 PHARMACEUTICALS, INC antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-09-30 was 15.63M shares, a 388.07% increase year-over-year.
- X4 PHARMACEUTICALS, INC antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-06-30 was 3.19M shares, a 1.62% increase year-over-year.
- X4 PHARMACEUTICALS, INC antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 14.70M shares, a 368.03% increase from fiscal 2024.
- X4 PHARMACEUTICALS, INC antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 3.14M shares, a 2.29% decline from fiscal 2023.
- X4 PHARMACEUTICALS, INC antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 3.21M shares, a 96.48% decline from fiscal 2022.
- X4 PHARMACEUTICALS, INC antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 91.42M shares, a 643.86% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 18.59M shares 10-Q · filed 2026-08-06 | 18.59M shares 10-Q · filed 2026-08-06 | ||||||
| 2026-03-31 | 18.46M shares 10-Q · filed 2026-05-06 | |||||||
| 2025-12-31 | 14.70M shares 10-K · filed 2026-03-17 | |||||||
| 2025-09-30 | 15.63M shares 10-Q · filed 2025-11-05 | 15.63M shares 10-Q · filed 2025-11-05 | ||||||
| 2025-06-30 | 3.19M shares 10-Q · filed 2026-08-06 | 3.19M shares 10-Q · filed 2025-08-08 | 3.19M shares 10-Q · filed 2026-08-06 | 3.19M shares 10-Q · filed 2025-08-08 | ||||
| 2025-03-31 | 3.12M shares 10-Q · filed 2026-05-06 | 3.12M shares 10-Q · filed 2025-05-01 | ||||||
| 2024-12-31 | 3.14M shares 10-K · filed 2026-03-17 | 94.22M shares 10-K · filed 2025-03-26 | ||||||
| 2024-09-30 | 3.20M shares 10-Q · filed 2025-11-05 | 96.08M shares 10-Q · filed 2024-11-13 | 3.20M shares 10-Q · filed 2025-11-05 | 95.94M shares 10-Q · filed 2024-11-13 | ||||
| 2024-06-30 | 3.14M shares 10-Q · filed 2025-08-08 | 94.09M shares 10-Q · filed 2024-08-08 | 3.14M shares 10-Q · filed 2025-08-08 | 94.09M shares 10-Q · filed 2024-08-08 | ||||
| 2024-03-31 | 3.22M shares 10-Q · filed 2025-05-01 | 96.70M shares 10-Q · filed 2024-05-07 | ||||||
| 2023-12-31 | 3.21M shares 10-K · filed 2026-03-17 | 89.37M shares 10-K · filed 2024-03-21 | ||||||
| 2023-09-30 | 91.39M shares 10-Q · filed 2024-11-13 | 91.39M shares 10-Q · filed 2024-11-13 | ||||||
| 2023-06-30 | 89.69M shares 10-Q · filed 2024-08-08 | 89.69M shares 10-Q · filed 2024-08-08 | ||||||
| 2023-03-31 | 96.39M shares 10-Q · filed 2024-05-07 | |||||||
| 2022-12-31 | 91.42M shares 10-K · filed 2025-03-26 | |||||||
| 2022-09-30 | 63.62M shares 10-Q · filed 2023-11-09 | 63.62M shares 10-Q · filed 2023-11-09 | ||||||
| 2022-06-30 | 13.17M shares 10-Q · filed 2023-08-10 | 13.17M shares 10-Q · filed 2023-08-10 | ||||||
| 2022-03-31 | 13.44M shares 10-Q · filed 2023-05-04 | |||||||
| 2021-12-31 | 12.29M shares 10-K · filed 2024-03-21 | |||||||
| 2021-09-30 | 12.31M shares 10-Q · filed 2022-11-03 | 12.31M shares 10-Q · filed 2022-11-03 | ||||||
| 2021-06-30 | 12.31M shares 10-Q · filed 2022-08-04 | 12.31M shares 10-Q · filed 2022-08-04 | ||||||
| 2021-03-31 | 12.47M shares 10-Q · filed 2022-05-12 | |||||||
| 2020-12-31 | 11.92M shares 10-K · filed 2023-03-21 | |||||||
| 2020-09-30 | 11.85M shares 10-Q · filed 2021-11-04 | 11.85M shares 10-Q · filed 2021-11-04 | ||||||
| 2020-06-30 | 12.03M shares 10-Q · filed 2021-08-03 | 12.03M shares 10-Q · filed 2021-08-03 | ||||||
| 2020-03-31 | 11.35M shares 10-Q · filed 2021-05-06 | |||||||
| 2019-12-31 | 11.18M shares 10-K · filed 2022-03-17 | |||||||
| 2019-09-30 | 5.75M shares 10-Q · filed 2020-11-05 | 5.63M shares 10-Q · filed 2019-11-07 | 5.75M shares 10-Q · filed 2020-11-05 | 5.63M shares 10-Q · filed 2019-11-07 | ||||
| 2019-06-30 | 5.75M shares 10-Q · filed 2020-08-04 | 5.63M shares 10-Q · filed 2019-08-07 | 5.75M shares 10-Q · filed 2020-08-04 | 5.63M shares 10-Q · filed 2019-08-07 | ||||
| 2019-03-31 | 1.53M shares 10-Q · filed 2020-05-07 | |||||||
| 2018-12-31 | 5.10M shares 10-K · filed 2021-03-19 | 2.20M shares 10-K · filed 2019-03-11 | ||||||
| 2018-09-30 | 5.00M shares 10-Q · filed 2019-11-07 | 5.00M shares 10-Q · filed 2019-11-07 | 2.06M shares 10-Q · filed 2018-11-09 | |||||
| 2018-06-30 | 4.51M shares 10-Q · filed 2019-08-07 | 4.51M shares 10-Q · filed 2019-08-07 | 2.11M shares 10-Q · filed 2018-08-13 | |||||
| 2018-03-31 | 4.52M shares 10-Q · filed 2019-05-15 | 2.12M shares 10-Q · filed 2018-05-10 | ||||||
| 2017-12-31 | 4.51M shares 10-K · filed 2020-03-12 | 1.41M shares 10-K · filed 2019-03-11 | ||||||
| 2017-09-30 | 8.39M shares 10-Q · filed 2018-11-09 | |||||||
| 2017-06-30 | 7.94M shares 10-Q · filed 2018-08-13 | |||||||
| 2017-03-31 | 2.34M shares 10-Q · filed 2018-05-10 | |||||||
| 2016-12-31 | 2.35M shares 10-K · filed 2019-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |